» Articles » PMID: 39272887

Regulation of Tumor Microenvironment Through YAP/TAZ Under Tumor Hypoxia

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Sep 14
PMID 39272887
Authors
Affiliations
Soon will be listed here.
Abstract

In solid tumors such as hepatocellular carcinoma (HCC), hypoxia is one of the important mechanisms of cancer development that closely influences cancer development, survival, and metastasis. The development of treatments for cancer was temporarily revolutionized by immunotherapy but continues to be constrained by limited response rates and the resistance and high costs required for the development of new and innovative strategies. In particular, solid tumors, including HCC, a multi-vascular tumor type, are sensitive to hypoxia and generate many blood vessels for metastasis and development, making it difficult to treat HCC, not only with immunotherapy but also with drugs targeting blood vessels. Therefore, in order to develop a treatment strategy for hypoxic tumors, various mechanisms must be explored and analyzed to treat these impregnable solid tumors. To date, tumor growth mechanisms linked to hypoxia are known to be complex and coexist with various signal pathways, but recently, mechanisms related to the Hippo signal pathway are emerging. Interestingly, Hippo YAP/TAZ, which appear during early tumor and normal tumor growth, and YAP/TAZ, which appear during hypoxia, help tumor growth and proliferation in different directions. Peculiarly, YAP/TAZ, which have different phosphorylation directions in the hypoxic environment of tumors, are involved in cancer proliferation and metastasis in various carcinomas, including HCC. Analyzing the mechanisms that regulate the function and expression of YAP in addition to HIF in the complex hypoxic environment of tumors may lead to a variety of anti-cancer strategies and combining HIF and YAP/TAZ may develop the potential to change the landscape of cancer treatment.

Citing Articles

Overview of hepatocarcinogenesis focusing on cellular origins of liver cancer stem cells: a narrative review.

Eun J J Yeungnam Med Sci. 2024; 42:3.

PMID: 39523770 PMC: 11812091. DOI: 10.12701/jyms.2024.01088.

References
1.
Strepkos D, Markouli M, Papavassiliou K, Papavassiliou A, Piperi C . Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options. Neuropathol Appl Neurobiol. 2021; 48(2):e12762. DOI: 10.1111/nan.12762. View

2.
Luo J, Deng L, Zou H, Guo Y, Tong T, Huang M . New insights into the ambivalent role of YAP/TAZ in human cancers. J Exp Clin Cancer Res. 2023; 42(1):130. PMC: 10201886. DOI: 10.1186/s13046-023-02704-2. View

3.
Zhang S, Zhou D . Role of the transcriptional coactivators YAP/TAZ in liver cancer. Curr Opin Cell Biol. 2019; 61:64-71. DOI: 10.1016/j.ceb.2019.07.006. View

4.
Hagenbeek T, Webster J, Kljavin N, Chang M, Pham T, Lee H . The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors. Sci Signal. 2018; 11(547). DOI: 10.1126/scisignal.aaj1757. View

5.
Zhang X, Li Y, Ma Y, Yang L, Wang T, Meng X . Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress. J Exp Clin Cancer Res. 2018; 37(1):216. PMC: 6123950. DOI: 10.1186/s13046-018-0892-2. View